【思璞锐与默沙东达成SPR2015全球独家授权协议,潜在总价值21.3亿美元】9月28日,上海思璞锐医药科技有限公司与默沙东共同宣布,双方已就在研临床前口服KRAS G12D抑制剂SPR2015达成全球独家授权协议。根据协议条款,思璞锐已授予默沙东SPR2015在全球范围内开发、生产及商业化的独家权利。思璞锐将获得4亿美元首付款,并有资格获得与多个适应症相关的开发、商业化及其他活动有关的特定里程碑付款。包括首付款在内,本次交易的潜在总价值最高可达21.3亿美元。该交易已完成交割。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.